MedTrace Logo

Methotrexate - Inadequate Response Device Sub-Study

NCT01173120 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2012-01-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

DEVICE

Abatacept combination product (ACP)

Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-02-28
Completion
2010-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01173120 on ClinicalTrials.gov